Pretreatment PD-L1 IHC scores were reported as a combined positive score (CPS) and assessed in tumor cells, macrophages, and lymphocytes; CPS PD-L1 was ≥1% in 78% of patients and PD-L1 positivity was associated with increased rates of pCR, as well as higher pretreatment and on-treatment stromal tumor-infiltrating lymphocytes (sTILs). This evidence concerns the gene CD274 and neoplasm.